Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2201
uniQure
QURE
$1.54B
| $5.02M | ﹤0.01% |
209,790
+94,228
| +82% | +$3.64M |
2020 Q2
22 quarters
|
|
|
DBRG
2202
DELISTED
DigitalBridge
DBRG
| $5.02M | ﹤0.01% |
327,217
-63,534
| -16% | -$763K |
2022 Q1
15 quarters
|
|
2203
Sarepta Therapeutics
SRPT
$1.83B
| $5.02M | ﹤0.01% |
233,149
-65,937
| -22% | -$1.39M |
2013 Q2
50 quarters
|
|
2204
Towne Bank
TOWN
$3.31B
| $5.01M | ﹤0.01% |
150,038
+27,313
| +22% | +$920K |
2016 Q2
38 quarters
|
|
2205
WaFd
WAFD
$2.24B
| $5M | ﹤0.01% |
156,051
+28,107
| +22% | +$868K |
2013 Q2
50 quarters
|
|
2206
Globalstar
GSAT
$10.8B
| $4.99M | ﹤0.01% |
81,766
+9,962
| +14% | +$550K |
2020 Q4
20 quarters
|
|
2207
PUT
CRISPR Therapeutics
CRSP
$5.29B
| $4.98M | ﹤0.01% |
95,000
-50,500
| -35% | -$3.02M |
2025 Q2
2 quarters
|
|
2208
Universal Display
OLED
$3.63B
| $4.98M | ﹤0.01% |
42,645
-2,852
| -6% | -$370K |
2013 Q2
50 quarters
|
|
2209
PUT
TeraWulf
WULF
$7.37B
| $4.96M | ﹤0.01% |
+431,500
| New | +$5.78M |
2025 Q4
0 quarters
|
|
2210
ePlus
PLUS
$2.43B
| $4.95M | ﹤0.01% |
56,415
+13,148
| +30% | +$1.08M |
2013 Q2
50 quarters
|
|
2211
Cactus
WHD
$4.53B
| $4.94M | ﹤0.01% |
108,166
+3,889
| +4% | +$163K |
2018 Q1
31 quarters
|
|
2212
RxSight
RXST
$198M
| $4.93M | ﹤0.01% |
473,567
+164,804
| +53% | +$1.65M |
2022 Q1
15 quarters
|
|
|
DEC
2213
Diversified Energy Company
DEC
$942M
| $4.93M | ﹤0.01% |
340,347
-32,084
| -9% | -$449K |
2023 Q4
8 quarters
|
|
2214
HUB Group
HUBG
$1.76B
| $4.93M | ﹤0.01% |
115,629
-763
| -0.7% | -$29K |
2016 Q1
39 quarters
|
|
2215
CALL
Zscaler
ZS
$33.3B
| $4.93M | ﹤0.01% |
21,900
| – | – |
2023 Q4
8 quarters
|
|
2216
Westlake Corp
WLK
$8.16B
| $4.93M | ﹤0.01% |
66,613
-35,049
| -34% | -$2.49M |
2013 Q2
50 quarters
|
|
2217
AvePoint
AVPT
$3.01B
| $4.92M | ﹤0.01% |
354,525
+142,988
| +68% | +$1.98M |
2022 Q1
15 quarters
|
|
2218
Pricesmart
PSMT
$5.28B
| $4.91M | ﹤0.01% |
40,048
+3,218
| +9% | +$393K |
2013 Q2
50 quarters
|
|
|
OPLN
2219
Openlane
OPLN
$4.36B
| $4.9M | ﹤0.01% |
164,607
+14,008
| +9% | +$379K |
2013 Q2
50 quarters
|
|
2220
CALL
Green Plains
GPRE
$1.07B
| $4.9M | ﹤0.01% |
500,000
| – | – |
2025 Q3
1 quarter
|
|
2221
SGHC Ltd
SGHC
$5.93B
| $4.9M | ﹤0.01% |
410,020
+114,244
| +39% | +$1.37M |
2022 Q4
12 quarters
|
|
|
DVAX
2222
DELISTED
Dynavax Technologies
DVAX
| $4.89M | ﹤0.01% |
317,848
-23,841
| -7% | -$263K |
2019 Q1
27 quarters
|
|
2223
Vanguard Intermediate-Term Bond ETF
BIV
$27.9B
| $4.88M | ﹤0.01% |
62,714
| – | – |
2020 Q2
22 quarters
|
|
2224
CONMED
CNMD
$1.41B
| $4.88M | ﹤0.01% |
120,205
-6,530
| -5% | -$284K |
2016 Q2
38 quarters
|
|
2225
Nurix Therapeutics
NRIX
$2.34B
| $4.87M | ﹤0.01% |
256,684
+11,589
| +5% | +$166K |
2022 Q1
15 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.